Motorized Spinal Decompression for Chronic Discogenic Low Back Pain:

Chart Review of 100 Outpatients



Alex Macario, MD, MBA, Stanford University;
Sunil J. Panchal, MD, COPE Foundation, Florida Pain Management;
Charlotte Richmond, PhD, Nema Research, Biomedical Research & Education Foundation;
Joseph V. Pergolizzi, Jr., MD, Johns Hopkins University & Nema Research

Motorized Spinal Decompression for Chronic Discogenic Low Back Pain:

Chart Review of 100 Outpatients

Alex Macario, MD, MBA, *Stanford University;*

Sunil J. Panchal, MD, *COPE Foundation, Florida Pain Management;*

Charlotte Richmond, PhD, *Nema Research, Biomedical Research & Education Foundation*

Joseph V. Pergolizzi, Jr., MD, *Johns Hopkins University & Nema Research*

ABSTRACT

Objective: Conduct retrospective chart audit to assess outcomes of a random sample of outpatients treated with motorized spinal decompression via the DRX9000™ for chronic low back pain lasting more than 12 weeks.

Methods: Data from charts of 100 adults cared for in 2004-2006 at four clinics, one hospital-based and three free-standing, were abstracted using a standardized data collection form. Protected health information was accessed in accordance with the HIPAA privacy rule. Workman's compensation patients were excluded. DRX sessions (28-30 mins each) were for 8 weeks (mean) with 4-5 sessions the first week tapering to one session/wk (mean treatments = 23). Treatment protocol included instruction on lumbar stretching exercises and ice or muscle stimulation after DRX sessions. Pain, analgesic use, and activities of daily living were assessed pre and post treatment.

Results: Subjects (62% female, 94% white, mean age 55, 53% employed) had mean pain score 5.99 on a 0 to 10 scale (0=no pain 10=worst pain) at time of initial presentation that decreased to 0.87 after last DRX treatment. NSAID (41% of patients) and opioid (24% of the patients) use decreased (<5%) after treatment.

Conclusion: Overall, patients' pain improved after DRX treatment, requiring fewer analgesics, with better function. Practice variability exists in how clinics use the DRX9000™.

OBJECTIVE

- Conduct retrospective chart audit to assess outcomes of a random sample of outpatients treated with motorized spinal decompression via the DRX9000™ for chronic low back pain lasting more than 12 weeks.

METHODS

- Data from charts of 100 adults cared for in 2004-2006 at four clinics, one hospital-based and three free-standing, were abstracted using a standardized data collection form.
- Protected health information was accessed in accordance with the HIPAA privacy rule.
- Workman's compensation patients were excluded.
- DRX sessions (28-30 mins each) were for 8 weeks (mean) with 4-5 sessions the first week tapering to one session/wk (mean treatments = 23).
- Treatment protocol included instruction on lumbar stretching exercises and ice or muscle stimulation after DRX sessions.
- Pain, analgesic use, and activities of daily living were assessed pre and post treatment.

RESULTS

- Subjects (62% female, 94% white, mean age 55, 53% employed) had mean pain score 5.99 on a 0 to 10 scale (0=no pain 10=worst pain) at time of initial presentation that decreased to 0.87 after last DRX treatment. NSAID (41% of patients) and opioid (24% of the patients) use decreased (<5%) after treatment (Fig. 1 - Fig 9).

DEMOGRAPHICS

Total Number of Patients = 100				
Mean Age	55		Mean Height	68 in
Female	62%		Mean Weight	89 kg
Employed	53%		White	94%
Retired	40%		Hispanic	3%
Disabled	5%		Black	2%
Housewife	1%		Asian	1%

FIGURE 1

MEDICAL DIAGNOSIS & SYMPTOMS

Medical Diagnosis		Symptoms	
Herniated Disc	74%	Nonspecific LBP	86%
Degenerative Disc Disease	66%	Leg Radiation	62%
Herniated & Degenerative Disc	26%	Radiation to Buttocks	22%
Sciatica	11%	Leg Pain > Back Pain	16%
Mean Duration Low Back Pain	260 wks	Prior Surgery	12%

FIGURE 2

MRI RESULTS PRE-TREATMENT

MRI Results		Level of Pathology	
Disc bulge	36%	L5-S1	35%
Degenerative Changes	28%	L4-L5	40%
Protrusion	28%	L3-L4	13%
Extrusion	5%	L2-L3	8%
		L1-L2	1%
		T12-L1	2%

FIGURE 3

TREATMENT PROTOCOL AT SITES

	Site A	Site B	Site C	Site D
Balance musculoskeletal system before DRX	Y	N	Y	Y
Heat before DRX	N	Y	N	N
Ice after DRX	Y	Y	Y	Y
Muscle stimulation after DRX	Y	N	Y	Y

FIGURE 4

LIMITING EFFECTS OF LBP ON ACTIVITIES OF DAILY LIVING

	Pre-DRX9000	Post-DRX9000
Bathing	25%	0%
Dressing	25%	0%
Walking	50%	1%
Sitting	50%	3%
Standing	51%	4%
Sleeping	21%	0%
None	1%	10%
Other	59%	1%
Unknown	9%	59%

FIGURE 5

ANALGESIC USE

Analgesic Use	Pre-DRX9000	Post-DRX9000
No meds	40%	20%
NSAIDs	43%	0%
Opioids	23%	0%
Muscle Relax	12%	1%
Steroids	4%	1%
Unknown	0%	59%

Cells do not add up to 100% as some patients were on more than one medication.

FIGURE 6

POST DRX FOLLOW UP SCHEDULE

0-3 months	3-6 months	6-9 months	> 9 months
50%	22%	9%	19%

FIGURE 7

PAIN VRS



FIGURE 8

LIMITING EFFECTS OF LBP ON ACTIVITIES OF DAILY LIVING

	Pre-DRX9000	Post-DRX9000
Bathing	25%	0%
Dressing	25%	0%
Walking	50%	1%
Sitting	50%	3%
Standing	51%	4%
Sleeping	21%	0%
None	1%	10%
Other	59%	1%
Unknown	9%	59%

FIGURE 5

OSWESTRY LBP DISABILITY INDEX



FIGURE 9

ANALGESIC USE

Analgesic Use	Pre-DRX9000	Post-DRX9000
No meds	40%	20%
NSAIDs	43%	0%
Opioids	23%	0%
Muscle Relax	12%	1%
Steroids	4%	1%
Unknown	0%	59%

Cells do not add up to 100% as some patients were on more than one medication.

FIGURE 6

RESULTS CONTINUED

- Patients reported a mean 90% improvement in back pain, and better function as measured by activities of daily living. On a 0 to 10 scale (0=Not satisfied 10=Very satisfied) patients rated the DRX9000™ an 8.98 (Fig. 10).
- No patient required more invasive therapies (e.g., surgery).

POST DRX FOLLOW UP SCHEDULE

0-3 months	3-6 months	6-9 months	> 9 months
50%	22%	9%	19%

FIGURE 7

PATIENT SATISFACTION

Mean satisfaction with DRX (0-10 scale) 0=not satisfied 10=Very satisfied	8.98
Improvement in LBP provided by DRX	90%
Recommend DRX to someone else	100%

Data based on 20-25% of patients contacted in follow up

FIGURE 10

PAIN VRS



FIGURE 8

CONCLUSION

Overall, patients' pain improved after DRX treatment, requiring fewer analgesics, with better function. Practice variability exists in how clinics use the DRX9000™. We didn't have control groups, making it difficult to know how much of the benefit was placebo or spontaneous recovery and how much was due to the intervention. Randomized double-blinded clinical trials are needed to measure the efficacy of non-surgical spinal decompression systems.